Andre Goy, MD, MS

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses immunotherapy agents currently being evaluated in the treatment of patients with mantle cell lymphoma.

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses novel agents approved for the treatment of patients with mantle cell lymphoma.

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the role of minimal residual disease in the treatment of patients with mantle cell lymphoma.

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses combination therapies currently being explored in the treatment of patients with mantle cell lymphoma.

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the history of bortezomib as a treatment for patients with mantle cell lymphoma.

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses phase III results of a study exploring rituximab as maintenance therapy after autologous stem cell transplantation in younger patients with mantle cell lymphoma.

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses how the treatment landscape of mantle cell lymphoma is evolving.

"Are you making progress?" is one of the questions you are most frequently being asked as an oncologist-even in social settings.

The classic saying Have a Happy and Healthy New Year takes a particularly important meaning this year, as Jan 1, 2014, is now a landmark date in the history of US healthcare with the implementation of the Affordable Care Act (ACA), also referred to as Obamacare

The real question is how will we best use our continually evolving armamentarium of treatments to deliver the best outcomes while optimizing the cost of care for our patients.

This issue of Contemporary Oncology includes a focus on 2 challenging situations: management of metastatic TNBC and of advanced stage NSCLC.

A look at the benefits of the chemoimmunotherapy rituximab for CLL and a look at the treatments and advances made in treating metastatic CRC.

A Letter from Andre Goy, MD, MS, about the New Frontiers in the Management of Solid and Liquid Tumors in November.

A look at dramatic changes in the landscape of multiple myeloma that have occurred over the past decade and new developments in the context of stem cell transplantation in non-Hodgkin lymphoma.

In this role, I hope to help the journal achieve its mission in bringing readers high-quality, peer-reviewed research, provocative commentaries, and personal patient stories.